^
Association details:
| Biomarker: | FLT3-ITD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor) + PRT811 (PRMT5 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
276 Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel Gilteritinib Combinations Targeting Oxidative Phosphorylation and De-Novo Purine Biosynthesis Pathways for FLT3-ITD+ Acute Myeloid Leukemia
Published date:
11/03/2022
Excerpt:
Our human FLT3-ITD AML xenograft model showed a promising survival benefit and tumor burden reduction provided by combination therapies of dinaciclib/gilteritinib, brequinar/gilteritinib, and PRT808/gilteritinib over monotherapies, suggesting that the three combinations may improve the outcome of AML patients with FLT3 mutations.
DOI:
https://doi.org/10.1182/blood-2022-165573
